| Cat. No. |
Size |
Price |
Figures |
|---|
RP13279-0.5 mg
| 0.5 mg | $ 57.00 | HPLC: 20060721145624 (PDF)
MS: 20060721145603 (PDF)
MSDS: 20080821033132 (PDF)
STRUCTURE:
Zoom
References:
- Ina Bergheim, et al. Critical Role of Plasminogen Activator Inhibitor-1 in Cholestatic Liver Injury and Fibrosis. J Pharmacol Exp Ther. Feb 2006; 316(2): 592-600.
- Katariina Cederqvist, et al. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome. Pediatrics. Apr 2006; 117(4): 1226-1234.
- K. Van Ness, V, et al. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthriti. Rheumatology (Oxford). Feb 2002; 41(2):136-141.
|
|---|
| Full Name | | Plasminogen Activator Inhibitor (PAI)-1 |
|
| Alias |
Plasminogen Activator Inhibitor1; PAI-1; PAI1 |
Sequence
(one-letter code) |
ARMAPE |
Sequence
(three-letter code) | {ALA}{ARG}{MET}{ALA}{PRO}{GLU} |
|---|
| Description | Plasminogen activator inhibitor-1 (PAI-1) is a 50,000 Da glycoprotein that belongs to the serine proteinase inhibitor superfamily which is the primary inhibitor of both tissue-type and urokinase-type plasminogen activators. The main function of PAI-1 is to decrease fibrinolysis, leading to fibrin accumulation, which is associated with thrombotic disease. The gene for PAI-1 may have a deletion/insertion polymorphism (4G/5G) located at -675 bp on chromosome 7 q 21.3-22. |
|---|
| Solubility | The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents. |
|---|
| Formula | C27H47N9O9S1 |
|---|
| M.W. | 673.79 |
|---|
| Purity | > 95% |
|---|
| Storage | Before use, store the peptide in the DRY form at 0°C - 5°C. For best and repeatable results, rehydrate the peptide immediately before use. Do not re-freeze any unused portion. |
